Date lodged: 10 February 2017
To ask the Scottish Government what consideration has been given to the provision of Oncotype DX genetic testing for women in Scotland.
Answered by: Shona Robison 6 March 2017
The Scottish Molecular Pathology Evaluation Panel provided an advice note in Oncotype DX in January 2016 which states that, “should a clinician consider that the molecular pathology test would assist in a decision on case management for a patient within the indication specified then the test should be undertaken”.
NHS Boards are responsible for providing services to meet the assessed needs of their resident populations taking into account relevant frameworks and guidance and within their annual allocations.